Profile photo

Cancer Biology With Katy Beckermann, MD, PhD

Oncology / Hematology

Dr. Katy Beckermann is a dedicated GU medical oncologist and clinical researcher. She is driven to provide exceptional care to patients facing the daunting diagnosis of cancer. Her passion lies in exploring the 'why' questions to propel our understanding forward and enhance treatment options through clinical trials.

Emerging Therapeutic Mechanisms and Imaging Advances in RCC

Dear Colleagues,

This year has seen the emergence of several novel mechanisms of action and imaging technologies in the field of renal cell carcinoma (RCC). Highlights include CAR T-cell therapies targeting CD70, offering an innovative immunotherapy approach, and advancements in HIF inhibitors addressing novel ways of targeting HIF biology. Novel PET imaging techniques, such as zirconium-labeled CAIX agents, are improving disease detection and monitoring, while new tyrosine kinase inhibitors (TKIs) like zanzalintinib are refining treatment by seeking to balance efficacy and tolerability. These developments underscore the exciting progress that continues to be made in RCC.

Sincerely,

Katy Beckermann, MD, PhD

 

Articles
  • Mashup Score: 177
    • Profile photo of montypal
      montypal

      Thank you to @CD_AACR for offering us the opportunity to publish our work, simultaneous with #AACR24! Grateful to @ElizSMcKenna for facilitating a thoughtful but rapid peer review process to get this out in time for the meeting.
      In #kidneycancer, we have been fortunate to have… https://t.co/0PaQ0T1H5s https://t.co/c9Q5PUrAK5 https://t.co/aMJFSweDUB

      Read the original tweet here

    Tweet Tweets with this article
    • Profile photo of katy-eby
      katy-eby

      Excitement is growing around CAR T-cell therapies for kidney cancer, with many companies exploring innovative targets and products.

  • Mashup Score: 65
    • Profile photo of neerajaiims
      neerajaiims

      Just in: Positive ph3 Zircon imaging study👉@telixpharma CA-9 PET/CT scan has 86% sensitivity & 87% specificity in detecting clear cell RCC non-invasively. Press release👉https://t.co/Ep3OHvhzPP Congrats Brian @KidneyCancerDoc #ColinHyaward @OncoAlert @kidneycan @KidneyCancer https://t.co/XZp3n9Jtej https://t.co/FArNWxXmi6

      Read the original tweet here

    Tweet Tweets with this article
    • Profile photo of katy-eby
      katy-eby

      Novel methods to image RCC which will presumably change care in localized disease states, advanced disease, and possibly be the next step for radioligand development in RCC.

  • Mashup Score: 52
    James Brugarolas on Twitter - 9 day(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of JBrugarolas
      JBrugarolas

      Congratulations to the team including Nizar @MDAndersonNews @brian_rini on first #siRNA #RCC phase 1 https://t.co/psbH7od9ms with @ArrowheadPharma #HIF2 siRNA building upon https://t.co/NXPPwD7cIW (PMID36190432) opening new field. https://t.co/mnmCsnviUz

  • Mashup Score: 62
    • Profile photo of BradMcG04
      BradMcG04

      Zanzalitinib with activity in refractory RCC with manageable safety profile even in those patients who had previously received cabozantinib @montypal @DrChoueiri @KidneyCancer https://t.co/tHk3x2ZFx8

      Read the original tweet here

    Tweet Tweets with this article
    • Profile photo of katy-eby
      katy-eby

      While not a novel mechanism, optimizing TKIs for improved efficacy and tolerability provides valuable additional treatment options for our patients look forward to seeing additional data in future on zanza.